Global Health Research Institute, Institute for Life Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.
Global Health Research Institute, Institute for Life Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.
J Infect. 2018 Jan;76(1):11-19. doi: 10.1016/j.jinf.2017.10.006. Epub 2017 Oct 20.
Infectious disease remains a significant burden in the UK and the focus of significant amounts of research investment each year. The Research Investments in Global Health study has systematically assessed levels of funding for infection research, and here considers investment alongside UK burden of individual infectious diseases.
The study included awards to UK institutions between 1997 and 2013 that were related to infectious disease. Awards related to global health projects were excluded here. UK burden data (mortality, years lived with disability, and disability adjusted life years) was sourced from the Global Burden of Disease study (IHME, USA). Awards were categorised by pathogen, disease, disease area and by type of science along the research pipeline (pre-clinical, phase I-III trials, product development, public health, cross-disciplinary research). New metrics present relative levels of funding by comparing sum investment with measures of disease burden.
There were 5685 relevant awards comprising investment of £2.4 billion. By disease, HIV received most funding (£369.7m; 15.6% of the total investment). Pre-clinical science was the predominant type of science (£1.6 billion, 68.7%), with the UK Medical Research Council (MRC) the largest funder (£714.8 million, 30.1%). There is a broad temporal trend to increased fundingper annum. Antimicrobial resistance received (£102.8 million, 4.2%), whilst sepsis received £23.6 million (1.0%). Compared alongside disease burden, acute hepatitis C and measles typically were relatively well-funded, whilst pneumonia, syphilis and gonorrhoea were poorly-funded.
The UK has a broad research portfolio across a wide range of infectious diseases and disciplines. There are notable strengths including HIV, some respiratory infections and in pre-clinical science, though there was less funding for UK-relevant trials and public health research. Compared to the UK burden of disease, syphilis, gonorrhoea and pneumonia appear relatively neglected. Investment analyses can assist support policymakers to increase the equity of the UK R&D landscape.
传染病在英国仍是一个重大负担，每年都有大量的研究投资集中于此。“全球健康研究投资”研究系统地评估了传染病研究的资金水平，本研究还考虑了传染病在英国的负担。
本研究纳入了 1997 年至 2013 年期间与传染病相关的英国机构的奖项。这里排除了与全球卫生项目相关的奖项。从全球疾病负担研究（美国 IHME）获得了英国疾病负担数据（死亡率、残疾生活年数和伤残调整生命年）。奖项按病原体、疾病、疾病领域以及研究管道（临床前、I-III 期试验、产品开发、公共卫生、跨学科研究）中的科学类型进行分类。新指标通过将投资总额与疾病负担指标进行比较，来衡量资金的相对水平。
共有 5685 项相关奖项，投资总额为 24 亿英镑。按疾病划分，艾滋病毒（HIV）获得的资金最多（3.697 亿英镑；占总投资的 15.6%）。临床前科学是最主要的科学类型（16 亿英镑，占 68.7%），英国医学研究理事会（MRC）是最大的资助者（7.148 亿英镑，占 30.1%）。每年的资金投入呈广泛的增长趋势。抗微生物药物耐药性（1.028 亿英镑，占 4.2%）和败血症（2360 万英镑，占 1.0%）获得了一定的资助。与疾病负担相比，急性丙型肝炎和麻疹的资金相对较多，而肺炎、梅毒和淋病的资金则较少。
英国在广泛的传染病和学科领域拥有广泛的研究组合。英国在 HIV、一些呼吸道感染和临床前科学方面具有显著优势，尽管在英国相关试验和公共卫生研究方面的资金较少。与英国的疾病负担相比，梅毒、淋病和肺炎似乎相对被忽视。投资分析可以帮助支持政策制定者提高英国研发领域的公平性。
